Evidence map›Paper›PMID 35621684›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.

Hiroki Sasamori, Kentaro Nakayama, Sultana Razia, Hitomi Yamashita, Tomoka Ishibashi, Masako Ishikawa, Seiya Sato, Satoru Nakayama, Yoshiro Otsuki, Ritsuto Fujiwaki and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Hiroki SasamoriDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Kentaro NakayamaDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Sultana RaziaDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Hitomi YamashitaDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Tomoka IshibashiDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Masako IshikawaDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Seiya SatoDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Satoru NakayamaDepartment of Obstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu 4308558, Japan.
Yoshiro OtsukiDepartment of Organ Pathology, Seirei Hamamatsu General Hospital, Hamamatsu 4308558, Japan.ORCID 0000-0002-0568-3811
Ritsuto FujiwakiDepartment of Obstetrics and Gynecology, Matsue Red Cross Hospital, Matsue 6908506, Japan.
Noriyoshi IshikawaDepartment of Pathology, Shonan Fujisawa Tokushukai Hospital, Fujisawa 2510041, Japan.
Satoru KyoDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.
Shimane University · JPSeirei Hamamatsu General Hospital · JPFujisawa City Hospital · JPMatsue Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian seromucinous tumors (SMBTs) are relatively rare, and their carcinogenesis is largely unknown. In this study, the molecular features of SMBTs in Japan are assessed. DNA was extracted from microdissected paraffin-embedded sections from 23 SMBT cases. Genetic mutations (

Indexed as

Ovarian NeoplasmsProto-Oncogene Proteins B-rafCarcinogenesisClass I Phosphatidylinositol 3-KinasesFemaleHumansJapanMutationProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Class I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53mutationoncogeneovarian seromucinous borderline tumorovarian tumortumor suppressor gene

Identifiers

PMID35621684
PMCPMC9139622
OpenAlexW4280623852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.